| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biophys J, October 2001, p. 1938-1946, Vol. 81, No. 4
and
*Institute of Protein Biochemistry and Enzymology, C.N.R., I-80125
Naples, Italy; and
Institute of Chemistry and Clinical
Chemistry, Faculty of Medicine, Catholic University "Sacro Cuore,"
I-00168 Rome, Italy
Hemoglobin function is modulated by several non-heme
ligands; among these effectors, organic phosphates generally bind to heterotropic sites with a one-to-one stoichiometry. The phosphate binding site of human hemoglobin is located at the interface between the two
chains. An additional binding site for polyanions has been
studied at the molecular level (Tamburrini, M., A. Riccio, M. Romano,
B. Giardina, and G. di Prisco. 2000. Eur. J. Biochem. 267:6089-6098) in the hemoglobins of the
south polar skua (Catharacta maccormicki). It is formed
by a cluster of six positive charges of both
chains (Val-1, Lys-99,
Arg-141); the two Lys-99
have an essential role in the site
structure. The present investigation, carried out on skua
deoxyhemoglobins by using a molecular dynamics approach, confirms the
structural feasibility of the additional site, possibly having the role
of an entry-leaving site, and leads to the proposal of a novel
migration pathway for phosphate along the central cavity of hemoglobin
from one binding site to the other, occurring according to the
hypothesis of a site-site migratory mechanism, which may assign a
functional role to the central cavity. The role of Lys-99
was
further confirmed by molecular dynamics experiments on the mutant
Lys-99
Ala in which, at the end of the simulation, the phosphate
was external to the additional site.
Biophys J, October 2001, p. 1938-1946, Vol. 81, No. 4
© 2001 by the Biophysical Society 0006-3495/01/10/1938/09 $2.00
This article has been cited by other articles:
![]() |
H. Vankayalapati, D. J. Bearss, J. W. Saldanha, R. M. Munoz, S. Rojanala, D. D. Von Hoff, and D. Mahadevan Targeting Aurora2 Kinase in Oncogenesis: A Structural Bioinformatics Approach to Target Validation and Rational Drug Design Mol. Cancer Ther., March 1, 2003; 2(3): 283 - 294. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |